- The two initial key clinical drivers for the collaborative were poor and deteriorating cancer health outcomes over the previous five-year period and increasing elective backlogs.
- The collaborative was formed in September 2020 as a response to the pandemic and a way to manage the practicalities and pressures of patient care across organisations.
- Sir David Nicholson was appointed as group chair of all participating organisations and the chair of the provider collaborative board in September 2022 to allow for cohesion and simplicity.
- The governance arrangements are moving towards a joint provider committee model to be in place by August 2023 to streamline and accelerate decision making.
- The clinical improvement programme has been the focus for the collaborative to date, with a growing emphasis on their corporate improvement programme as a response to the financial realities of the system post Covid-19.
- The first six clinical networks were developed in response to their key clinical issues, and they have since developed a further five clinical networks.
- All clinical networks have clinical leads who are funded for one day a week and who were recruited with both an emphasis on relationship building and a mindfulness to equal representation across organisations.
- The board play a key part in building momentum and engagement in the work of the collaborative. By approving programmes, integrating themselves within clinical networks and being visible in their support for the collaborative, they reinforce the message that the collaborative is valuable and a leadership priority.
- Two clinical summits take place each year with clinical network teams and executives attending to share updates, learning and progress in person.
- Getting it right first time data is being used by clinical networks as a way of identifying areas for improvement and measuring the effectiveness of their improvement work.
- Improvements are now being delivered across the collaborative's clinical networks including the system-wide roll out of tele dermatology, the acquisition of new robotic equipment at two additional trusts and the implementation of Mohs micrographic specialist surgery within the integrated care system.